Sirio Pharma Co., Ltd.

SZSE:300791 Voorraadrapport

Marktkapitalisatie: CN¥7.1b

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Sirio Pharma Toekomstige groei

Future criteriumcontroles 3/6

Sirio Pharma is forecast to grow earnings and revenue by 21.9% and 14.4% per annum respectively. EPS is expected to grow by 21.7% per annum. Return on equity is forecast to be 17.4% in 3 years.

Belangrijke informatie

21.9%

Groei van de winst

21.7%

Groei van de winst per aandeel

Personal Products winstgroei21.1%
Inkomstengroei14.4%
Toekomstig rendement op eigen vermogen17.4%
Dekking van analisten

Good

Laatst bijgewerkt26 Sep 2024

Recente toekomstige groei-updates

Recent updates

The Market Lifts Sirio Pharma Co., Ltd. (SZSE:300791) Shares 27% But It Can Do More

Sep 30
The Market Lifts Sirio Pharma Co., Ltd. (SZSE:300791) Shares 27% But It Can Do More

Is Sirio Pharma (SZSE:300791) Using Too Much Debt?

Sep 23
Is Sirio Pharma (SZSE:300791) Using Too Much Debt?

Sirio Pharma Co., Ltd.'s (SZSE:300791) Prospects Need A Boost To Lift Shares

Aug 01
Sirio Pharma Co., Ltd.'s (SZSE:300791) Prospects Need A Boost To Lift Shares

Sirio Pharma (SZSE:300791) Will Be Hoping To Turn Its Returns On Capital Around

Jun 30
Sirio Pharma (SZSE:300791) Will Be Hoping To Turn Its Returns On Capital Around

Is Sirio Pharma (SZSE:300791) A Risky Investment?

Jun 12
Is Sirio Pharma (SZSE:300791) A Risky Investment?

An Intrinsic Calculation For Sirio Pharma Co., Ltd. (SZSE:300791) Suggests It's 24% Undervalued

Apr 24
An Intrinsic Calculation For Sirio Pharma Co., Ltd. (SZSE:300791) Suggests It's 24% Undervalued

Sirio Pharma (SZSE:300791) Seems To Use Debt Quite Sensibly

Mar 06
Sirio Pharma (SZSE:300791) Seems To Use Debt Quite Sensibly

Winst- en omzetgroeiprognoses

SZSE:300791 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CNY Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/20265,758584N/A8564
12/31/20255,046484N/A7135
12/31/20244,356393N/A5885
6/30/20244,028334-82361N/A
3/31/20243,831315-155276N/A
12/31/20233,582281-66386N/A
9/30/20233,22222113393N/A
6/30/20232,94120464370N/A
3/31/20232,78822734344N/A
1/1/20232,507212151445N/A
9/30/20222,40920812388N/A
6/30/20222,315196-74397N/A
3/31/20222,283189-72461N/A
12/31/20212,369232-183341N/A
9/30/20212,361272-96384N/A
6/30/20212,316279-32367N/A
3/31/20212,216265-52257N/A
12/31/20202,06725796320N/A
9/30/20201,86520985272N/A
6/30/20201,71017840203N/A
3/31/20201,55415645206N/A
12/31/20191,58014365232N/A
9/30/20191,62518679236N/A
12/31/20181,595203-56183N/A
12/31/20171,330104N/A49N/A
12/31/2016786704N/A-98N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: 300791's forecast earnings growth (21.9% per year) is above the savings rate (2.9%).

Winst versus markt: 300791's earnings (21.9% per year) are forecast to grow slower than the CN market (23.2% per year).

Hoge groeiwinsten: 300791's earnings are expected to grow significantly over the next 3 years.

Omzet versus markt: 300791's revenue (14.4% per year) is forecast to grow faster than the CN market (13.2% per year).

Hoge groei-inkomsten: 300791's revenue (14.4% per year) is forecast to grow slower than 20% per year.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: 300791's Return on Equity is forecast to be low in 3 years time (17.4%).

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y